Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
Copyright © 2022 Arrazuria, Kerscher, Huber, Hoover, Lundberg, Hansen, Sordello, Renard, Aranzana-Climent, Hughes, Gribbon, Friberg and Bekeredjian-Ding..
Antimicrobial resistance has become one of the greatest threats to human health, and new antibacterial treatments are urgently needed. As a tool to develop novel therapies, animal models are essential to bridge the gap between preclinical and clinical research. However, despite common usage of in vivo models that mimic clinical infection, translational challenges remain high. Standardization of in vivo models is deemed necessary to improve the robustness and reproducibility of preclinical studies and thus translational research. The European Innovative Medicines Initiative (IMI)-funded "Collaboration for prevention and treatment of MDR bacterial infections" (COMBINE) consortium, aims to develop a standardized, quality-controlled murine pneumonia model for preclinical efficacy testing of novel anti-infective candidates and to improve tools for the translation of preclinical data to the clinic. In this review of murine pneumonia model data published in the last 10 years, we present our findings of considerable variability in the protocols employed for testing the efficacy of antimicrobial compounds using this in vivo model. Based on specific inclusion criteria, fifty-three studies focusing on antimicrobial assessment against Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii were reviewed in detail. The data revealed marked differences in the experimental design of the murine pneumonia models employed in the literature. Notably, several differences were observed in variables that are expected to impact the obtained results, such as the immune status of the animals, the age, infection route and sample processing, highlighting the necessity of a standardized model.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in microbiology - 13(2022) vom: 19., Seite 988728 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arrazuria, Rakel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimicrobial |
|---|
| Anmerkungen: |
Date Revised 28.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmicb.2022.988728 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346765013 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346765013 | ||
| 003 | DE-627 | ||
| 005 | 20231226032230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmicb.2022.988728 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346765013 | ||
| 035 | |a (NLM)36160241 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arrazuria, Rakel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Arrazuria, Kerscher, Huber, Hoover, Lundberg, Hansen, Sordello, Renard, Aranzana-Climent, Hughes, Gribbon, Friberg and Bekeredjian-Ding. | ||
| 520 | |a Antimicrobial resistance has become one of the greatest threats to human health, and new antibacterial treatments are urgently needed. As a tool to develop novel therapies, animal models are essential to bridge the gap between preclinical and clinical research. However, despite common usage of in vivo models that mimic clinical infection, translational challenges remain high. Standardization of in vivo models is deemed necessary to improve the robustness and reproducibility of preclinical studies and thus translational research. The European Innovative Medicines Initiative (IMI)-funded "Collaboration for prevention and treatment of MDR bacterial infections" (COMBINE) consortium, aims to develop a standardized, quality-controlled murine pneumonia model for preclinical efficacy testing of novel anti-infective candidates and to improve tools for the translation of preclinical data to the clinic. In this review of murine pneumonia model data published in the last 10 years, we present our findings of considerable variability in the protocols employed for testing the efficacy of antimicrobial compounds using this in vivo model. Based on specific inclusion criteria, fifty-three studies focusing on antimicrobial assessment against Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii were reviewed in detail. The data revealed marked differences in the experimental design of the murine pneumonia models employed in the literature. Notably, several differences were observed in variables that are expected to impact the obtained results, such as the immune status of the animals, the age, infection route and sample processing, highlighting the necessity of a standardized model | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Gram-negative | |
| 650 | 4 | |a PK/PD | |
| 650 | 4 | |a antimicrobial | |
| 650 | 4 | |a antimicrobial efficacy studies | |
| 650 | 4 | |a lung infection | |
| 650 | 4 | |a murine pneumonia model | |
| 700 | 1 | |a Kerscher, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Karen E |e verfasserin |4 aut | |
| 700 | 1 | |a Hoover, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Lundberg, Carina Vingsbo |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Jon Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Sordello, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Renard, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Aranzana-Climent, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Diarmaid |e verfasserin |4 aut | |
| 700 | 1 | |a Gribbon, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Friberg, Lena E |e verfasserin |4 aut | |
| 700 | 1 | |a Bekeredjian-Ding, Isabelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in microbiology |d 2010 |g 13(2022) vom: 19., Seite 988728 |w (DE-627)NLM208040617 |x 1664-302X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:19 |g pages:988728 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmicb.2022.988728 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 19 |h 988728 | ||